BNC Wealth Management’s Anavex Life Sciences AVXL Stock Holding History

BNC Wealth Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$22.7K	Hold	11,250	–	–	0.01%	104
2026 Q2	$29.1K	Hold	11,250	–	–	0.01%	106
2026 Q1	$34.5K	Sell	11,250 -1,000	-8%	-$4.33K	0.01%	106
2025 Q4	$43.6K	Buy	12,250 +2,000	+20%	+$12.3K	0.01%	106
2025 Q3	$91.2K	Hold	10,250	–	–	0.02%	106
2025 Q2	$94.5K	Hold	10,250	–	–	0.03%	97
2025 Q1	$87.9K	Hold	10,250	–	–	0.03%	97
2024 Q4	$110K	Hold	10,250	–	–	0.04%	95
2024 Q3	$58.2K	Hold	10,250	–	–	0.02%	92
2024 Q2	$43.3K	Sell	10,250 -6,850	-40%	-$27.7K	0.02%	99
2024 Q1	$87K	Hold	17,100	–	–	0.04%	101
2023 Q4	$159K	Buy	17,100 +500	+3%	+$3.44K	0.08%	93
2023 Q3	$109K	Buy	16,600 +3,550	+27%	+$28.3K	0.06%	95
2023 Q2	$106K	Hold	13,050	–	–	0.06%	97
2023 Q1	$112K	Buy	+13,050	New	+$130K	0.06%	105
2020 Q4	–	Sell	-5,550	Closed	-$25K	–	124
2020 Q3	$25K	Buy	+5,550	New	+$23.9K	0.02%	203

Other funds holding AVXL

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

LexAurum Advisors Overland Park, Kansas $893M AUM

Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return

Forum Financial Management Lombard, Illinois $7.7B AUM 11.59% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

BNC Wealth Management's AVXL Position: Q3 2026 in Review

BNC Wealth Management held its Anavex Life Sciences (AVXL) position steady in Q3 2026 at 11,250 shares worth $22.7K. The position accounts for 0.01% of the portfolio, ranked #104.

BNC Wealth Management first reported a position in AVXL in Q3 2020 and has held it in 16 quarters since. The position peaked at $159K in Q4 2023. 24 funds tracked by Wall St. Rank hold AVXL as of Q3 2026.

BNC Wealth Management held 11,250 shares of Anavex Life Sciences worth $22.7K as of Q3 2026.
BNC Wealth Management left its Anavex Life Sciences share count unchanged in Q3 2026.
Anavex Life Sciences made up 0.01% of BNC Wealth Management's portfolio in Q3 2026, its #104 holding.
BNC Wealth Management first reported a position in Anavex Life Sciences in Q3 2020 and has held it in 16 quarters since.
BNC Wealth Management's Anavex Life Sciences position peaked at $159K in Q4 2023.
24 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2026.

Based on BNC Wealth Management's 13F filing for Q3 2026, filed 19 Oct 2026.